Vivus reports bigger-than-expected 4th-qtr loss
Feb 25 (Reuters) - Vivus Inc's revenue for the first full quarter of selling its diet pill Qsymia fell short of analysts' estimates, and it posted a bigger-than-expected loss related to higher marketing expenses.
The company's fourth-quarter net loss rose to $56.7 million, or 56 cents per share, from $11.5 million, or 13 cents per share, a year earlier.
Net product revenue, reflecting sales of Qsymia, was $2 million in the fourth quarter, compared with $41,000 reported in the third quarter.
Vivus started generating revenue from the third quarter, when it began selling Qsymia.
- Deadly gun attack in eastern Ukraine shakes fragile Geneva accord |
- Japan expands army footprint for first time in 40 years, risks angering China
- Pfizer considers $100 billion bid for AstraZeneca: report
- Prosecutors extend Korea ferry captain's detention as death toll mounts |
- Rubin 'Hurricane' Carter, U.S. boxer famous in folk song, dies at 76